Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA108445 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Genome-wide assessment of gene expression in primary acute lymphoblastic leukemia cells was performed to identify genomic determinants of MTX’s antileukemic effects. Reduction of circulating leukemia cells after in vivo methotrexate treatment served as a measure MTX's antileukemic effects. Keywords: gene expression associated with drug response
2008-03-15 | GSE10255 | GEO
Project description:Genome-wide assessment of gene expression in primary acute lymphoblastic leukemia cells was performed to identify genomic determinants of MTXâs antileukemic effects. Reduction of circulating leukemia cells after in vivo methotrexate treatment served as a measure MTX's antileukemic effects. Experiment Overall Design: Gene expression in diagnostic primary acute lymphoblastic leukemia cells from bone marrow of 161 pediatric patients
2008-04-06 | E-GEOD-10255 | biostudies-arrayexpress
Project description:Treatment and prophylaxis of the central nervous system (CNS) is a critical component of acute lymphoblastic leukemia (ALL) therapy. However, CNS-directed therapies are a significant cause of morbidity and CNS relapse remains a cause of treatment failure. CNS-directed ALL therapies must target leukemia cells within cerebrospinal fluid (CSF), a fluid that is compositionally distinct from plasma and has been shown to impact leukemia biology. Herein, we demonstrate that human CSF attenuates the potency and efficacy of anti-folate drugs including methotrexate, the primary CNS-directed chemotherapeutic for over six decades. Importantly, this effect of CSF on leukemia methotrexate sensitivity was reversible. Additional mechanistic studies support that diminished proliferation and activation of the integrated stress response (ISR) in leukemia cells in CSF contribute to this resistance. Our findings suggest potential strategies to enhance methotrexate efficacy in CNS-directed ALL therapy and highlight the need to critically reassess even established standards of care.
2024-09-23 | GSE274857 | GEO
Project description:chemotherapy cross-resistance and treatment response in childhood acute lymphoblastic leukemia
| PRJNA91647 | ENA
Project description:Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in pediatric age, worldwide 487,294 new cases were reported, with 305,405 deaths in both sexes in 2022. In Mexico, more than 5,000 new cases were reported. One of the main treatments for ALL is chemotherapy, which consists of a complete treatment scheme of induction, consolidation (intensification), and maintenance, to eradicate the cancer. However, after induction treatment, 10-20% of patients relapse due to chemoresistance. Therefore, it is necessary to delve deeper into the molecular mechanisms underlying chemoresistance to identify new treatment strategies to diminish or reverse it. This project focuses on the identification of proteins associated with mechanisms of chemoresistance to vincristine (VCR) and methotrexate (MTX) administered during the induction phase using proteomic (LC/MS-MS) and bioinformatic analyses. Processes related to non-response to treatment include those involving the structure and functional dynamics of the cytoskeleton, as well as nucleic acid metabolism, DNA repair, and RNA processing. TYMP and GSN were selected as differentially expressed proteins associated with these enriched processes. Validation experiments in patient samples confirm TYMP and GSN as overexpressed proteins in non-responders to vincristine and methotrexate treatment administered in the induction phase of ALL treatment. Both proteins are associated with cytoskeleton dynamics and nucleic acid metabolism, processes that are Hallmarks of chemoresistance in acute lymphoblastic leukemia.
2026-02-06 | PXD074132 |
Project description:Digital gene expression profiling of primary acute lymphoblastic leukemia cells
| PRJNA142169 | ENA
Project description:Gene expression profiling of primary acute lymphoblastic leukemia (ALL) cells
| PRJNA142009 | ENA
Project description:Germline genomic variations associated with childhood acute lymphoblastic leukemia
| PRJNA119223 | ENA
Project description:To elucidate the genomics of cellular responses to cancer treatment, we analyzed the expression of over 9,600 human genes in acute lymphoblastic leukemia cells before and after in vivo treatment with methotrexate and mercaptopurine given alone or in combination. Based on changes in gene expression, we identified 124 genes that accurately discriminated among the four treatments. Discriminating genes included those involved in apoptosis, mismatch repair, cell cycle control and stress response. Only 14% of genes that changed when these medications were given as single agents also changed when they were given together. These data indicate that lymphoid leukemia cells of different molecular subtypes share common pathways of genomic response to the same treatment, that changes in gene expression are treatment-specific and that gene expression can illuminate differences in cellular response to drug combinations versus single agents.
2007-12-13 | E-GEOD-412 | biostudies-arrayexpress